Evidence map›Paper›PMID 30804122›Full record

ArticleIn vivo (Athens, Greece)

Altered Resistin Concentrations in Mid-trimester Amniotic Fluid of Fetuses With Trisomies 18 and 13: A Window onto the Pathophysiology of Trisomies 18 and 13.

Nikolaos Vrachnis, Erminia Dalakli, Dimitrios Zygouris, Nikolaos Vlachadis, Nikolaos Salakos, Dimitrios Botsis, Sophia Kalantaridou, Nikolaos Drakoulis, George Mastorakos, George Creatsas and 2 more

Open access · diamondAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in In vivo (Athens, Greece). The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.3field-weighted citation impact, top 39% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 2 citations in OpenAlex.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 1 institution in 1 country.

Nikolaos Vrachnis *Third Department of Obstetrics and Gynecology, School of Medicine, Attikon Hospital, National and Kapodistrian University of Athens, Athens, Greece nvrachnis@hotmail.com.
Erminia Dalakli *Third Department of Obstetrics and Gynecology, School of Medicine, Attikon Hospital, National and Kapodistrian University of Athens, Athens, Greece.
Dimitrios ZygourisThird Department of Obstetrics and Gynecology, School of Medicine, Attikon Hospital, National and Kapodistrian University of Athens, Athens, Greece.
Nikolaos VlachadisSecond Department of Obstetrics and Gynecology, School of Medicine, National and Kapodistrian University of Athens, Aretaieio Hospital, Athens, Greece.
Nikolaos SalakosSecond Department of Obstetrics and Gynecology, School of Medicine, National and Kapodistrian University of Athens, Aretaieio Hospital, Athens, Greece.
Dimitrios BotsisSecond Department of Obstetrics and Gynecology, School of Medicine, National and Kapodistrian University of Athens, Aretaieio Hospital, Athens, Greece.
Sophia KalantaridouThird Department of Obstetrics and Gynecology, School of Medicine, Attikon Hospital, National and Kapodistrian University of Athens, Athens, Greece.
Nikolaos DrakoulisDepartment of Pharmaceutical Technology, Faculty of Pharmacy, National and Kapodistrian University of Athens, Athens, Greece.ORCID https://orcid.org/0000-0001-9067-5308
George MastorakosUnit of Endocrinology, Diabetes mellitus and Metabolism, Second Department of Obstetrics and Gynecology, School of Medicine, National and Kapodistrian University of Athens, Aretaieio Hospital, Athens, Greece.
George CreatsasSecond Department of Obstetrics and Gynecology, School of Medicine, National and Kapodistrian University of Athens, Aretaieio Hospital, Athens, Greece.
Efthymios DeligeoroglouSecond Department of Obstetrics and Gynecology, School of Medicine, National and Kapodistrian University of Athens, Aretaieio Hospital, Athens, Greece.
Zoe IliodromitiNeonatal Department, School of Medicine, National and Kapodistrian University of Athens, Aretaieio Hospital, Athens, Greece.
National and Kapodistrian University of Athens · GR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

BACKGROUND/

aimThe study aimed to examine whether resistin is present in second trimester amniotic fluid from pregnancies with trisomy 18 and 13 and evaluate its concentration in comparison with euploid pregnancies. PATIENTS AND

methodsThe study included 37 women who underwent amniocentesis. Eleven fetuses had trisomy 18, 3 had trisomy 13, while 23 had a normal karyotype.

resultsResistin was detected in all cases. The mean level of resistin in trisomy 18 was statistically significantly lower compared to euploid controls. Resistin levels in all abnormal cases were below its median concentration in euploid controls. ROC analysis showed very good prognostic value for both trisomies.

conclusionResistin is a constituent of mid-trimester amniotic fluid of pregnancies with trisomies 13 and 18, exhibiting lower levels than those in euploid fetuses. The reduced levels of resistin in amniotic fluid may be associated with early changes in metabolic pathways and immunoinflammatory responses.

Indexed as

AdultAmniotic FluidChromosomes, Human, Pair 13FemaleGestational AgeHumansPregnancyPregnancy Trimester, SecondResistinTrisomy 18 SyndromeResistinRETN protein, humanamniotic fluidcytokinesEdwards syndromePatau syndromepregnancyResistintrisomy 13trisomy 18

Identifiers

PMID30804122
PMCPMC6506289
OpenAlexW2915285135

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.